Phase 2 studies are ongoing to assess the efficacy and safety of ADX-038 in patients with complement-mediated diseases – SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback